CRB-701 Receives FDA Fast Track Designation for Relapsed/Refractory Cervical Cancer
The FDA granted fast track designation to CRB-701 for the treatment of adult patients with relapsed/refractory metastatic cervical cancer.
Related Articles
Assessing the impact of response to HMA-based therapy on survival outcomes in HR-MDS
Benjamin Rolles, MD, Brigham and Women’s Hospital, Boston, MA, comments on the results of an analysis from the International Consortium for MDS (icMDS) VALIDATE Database,…
Risk-Reducing Surgery Improves Survival Outcomes in Younger BRCA+ Breast Cancer
Risk-reducing surgery improved survival outcomes in younger patients with breast cancer and a germline BRCA mutation.
ASH 2024: Late-breaking abstract rundown
VJHemOnc is excited to share a feature covering the late-breaking abstracts presented at the 66th ASH Annual Meeting & Exposition.
T-DXd Improves PFS Irrespective of Time to Progression, Type of Endocrine Resistance in HER2-Low/-Ultralow Metastatic Breast Cancer
T-DXd improved PFS vs treatment of physician’s choice in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer.
Dr Gerds on Efficacy Data Supporting the Use of Momelotinib in Myelofibrosis With Anemia
Aaron Gerds, MD, discusses data from the SIMPLIFY-1 and MOMENTUM trials which support the use of momelotinib in myelofibrosis with anemia.
Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer
Elacestrant was partnered with multiple targeted agents across varying dose levels and schedules for patients with estrogen receptor–positive advanced breast cancer.
Turning grief into purpose
Full of stamina and determination, Lynn Lippert supported others and did what she loved through 24 years of living with metastatic breast cancer. Lippert’s life…
Healing Visual Arts Program Offers New Strategy for Artwork at Fox Chase Cancer Center and Network Locations
Art remains a vital part of Fox Chase Cancer Center’s culture. From the symbolic sculpture, The Diamond, greeting visitors outside the main entrance to the…
An Overview of the Treatment Landscape for Anemia Management in LR-MDS
Thomas W. LeBlanc, MD, MA, discusses how the standard of care (SOC) options for anemia management in patients with low-risk myelodysplastic syndromes (LR-MDS) typically involve…
